Evidence map›Paper›PMID 27810088›Full record

ReviewMayo Clinic proceedings2016

The Promise and Peril of Precision Medicine: Phenotyping Still Matters Most.

Jaeger P Ackerman, Daniel C Bartos, Jamie D Kapplinger, David J Tester, Brian P Delisle, Michael J Ackerman

Open access · bronzeAbstract readReview
In one paragraph

Review in Mayo Clinic proceedings, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Multi-site validation of a functional assay to adjudicatemedRxiv : the preprint server for health sciences · 2023
    Article
  11. Review
  12. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2022
    Article
  13. Article
  14. Article
  15. Review
  16. Variant interpretation in molecular autopsy: a useful dilemma.International journal of legal medicine · 2022
    Article
  17. Challenges in genetic testing: clinician variant interpretation processes and the impact on clinical care.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Article
  18. Article
  19. Cardiogenetics, 25 years a growing subspecialism.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2020
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Jaeger P AckermanDivision of Heart Rhythm Services, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; Division of Pediatric Cardiology, Department of Pediatrics, Mayo Clinic, Rochester, MN; Windland Smith Rice Sudden Death Genomics Laboratory, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN.
Daniel C BartosDepartment of Physiology, Center for Muscle Biology, University of Kentucky, Lexington, KY; Department of Pharmacology, University of California, Davis, CA.
Jamie D KapplingerDivision of Heart Rhythm Services, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; Division of Pediatric Cardiology, Department of Pediatrics, Mayo Clinic, Rochester, MN; Windland Smith Rice Sudden Death Genomics Laboratory, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN.
David J TesterDivision of Heart Rhythm Services, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; Division of Pediatric Cardiology, Department of Pediatrics, Mayo Clinic, Rochester, MN; Windland Smith Rice Sudden Death Genomics Laboratory, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN.
Brian P DelisleDepartment of Physiology, Center for Muscle Biology, University of Kentucky, Lexington, KY.
Michael J AckermanDivision of Heart Rhythm Services, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; Division of Pediatric Cardiology, Department of Pediatrics, Mayo Clinic, Rochester, MN; Windland Smith Rice Sudden Death Genomics Laboratory, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN. Electronic address: ackerman.michael@mayo.edu.
Mayo Clinic in Arizona · USMayo Clinic · USUniversity of California, Davis · USUniversity of Kentucky · US

Funding

Cardiac Channel Mutations in Sudden Infant Death Syndrome (SIDS)R01HD042569 · NICHD · MAYO CLINIC ROCHESTER · PI ACKERMAN, MICHAEL JOHN · 2002 to 2017
$6.9M
Allele-specific RNA Interference Targeting Synonymous Polymorphisms in KCNQ1 as a Novel Therapeutic for Long QT SyndromeF30HL127904 · NHLBI · MAYO CLINIC ROCHESTER · PI KAPPLINGER, JAMIE DUANE · 2015 to 2016
$93k
NHLBI NIH HHS F30 HL127904NICHD NIH HHS R01 HD042569
6 · The paper itself

Abstract

We illustrate the work necessary to reverse course after identification of a KCNQ1 variant interpreted erroneously as causing long QT syndrome (LQTS) and to identify the true cause of a case of sudden death in the young. Surrogate genetic testing of a decedent's living brother identified a rare KCNQ1-V133I variant, which prompted an implantable cardioverter defibrillator and subsequent diagnosis of LQTS in other family members. Subsequently, this presumed LQT1 family came to our institution for further clinical evaluation and research-based investigations, including KCNQ1-V133I variant-specific analysis of the decedent, heterologous expression studies of KCNQ1-V133I, and a whole-exome molecular autopsy along with genomic triangulation using his unaffected parents' DNA. After evaluating several V133I-positive family members, clinical doubt was cast on the veracity of the previously levied diagnosis of LQT1, resulting in a re-opening of the case and an intense pursuit of the lethal substrate. Furthermore, the decedent tested negative for V133I, and heterologous expression studies demonstrated a normal cellular phenotype for V133I-containing Kv7.1 channels. Instead, after whole-exome molecular autopsy, a de novo pathogenic variant (p.R454W) in DES-encoded desmin was identified. As detailed herein, the forensic evaluation of sudden death in the young requires meticulous focus on the decedent followed by a careful and deliberate assessment of the decedent's relatives. Surrogate genetic testing can have disastrous consequences and should be avoided. Genetic test results require careful scrutiny to avoid unintended and potentially devastating repercussions. Although the root cause of the decedent's tragic death would have remained a mystery, the unintended consequences for the living relatives described herein might have been avoided based on clinical grounds alone. All family members had electrocardiograms with normal QT intervals, making the diagnosis of familial LQTS unlikely. As such, if the clinicians caring for these patients had focused solely on clinical data from the survivors, there might have been no reason to embark on a path of inappropriate treatment based on genetic testing.

Identifiers

PMID27810088
PMCPMC6365209
OpenAlexW2548394018

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.